{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:06:26Z","timestamp":1788930386194,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11596-022-2672-7","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T10:03:34Z","timestamp":1671617014000},"page":"1178-1185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Development and Validation of a Nomogram for Predicting the 1-, 3-, and 5-year Survival in Patients with Acinar-predominant Lung Adenocarcinoma"],"prefix":"10.1007","volume":"42","author":[{"given":"Zhi-chao","family":"Zuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-de","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan-ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,21]]},"reference":[{"issue":"9","key":"2672_CR1","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol, 2015,10(9):1243\u20131260","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2672_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.annpat.2015.11.010","volume":"36","author":"S Lantuejoul","year":"2016","unstructured":"Lantuejoul S, Rouquette I, Brambilla E, et al. New WHO classification of lung adenocarcinoma and preneoplasia. Ann Pathol,2016,36(1):5\u201314","journal-title":"Ann Pathol"},{"issue":"30","key":"2672_CR3","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1200\/JCO.2014.58.8335","volume":"33","author":"MS Tsao","year":"2015","unstructured":"Tsao MS, Marguet S, Le Teuff G, et al. Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. J Clin Oncol, 2015,33(30):3439\u20133346","journal-title":"J Clin Oncol"},{"key":"2672_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.lungcan.2020.01.018","volume":"141","author":"M Ito","year":"2020","unstructured":"Ito M, Miyata Y, Tsutani Y, et al. Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis. Lung Cancer, 2020,141:107\u2013113","journal-title":"Lung Cancer"},{"issue":"3","key":"2672_CR5","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1378\/chest.13-2499","volume":"146","author":"A Mansuet-Lupo","year":"2014","unstructured":"Mansuet-Lupo A, Bobbio A, Blons H, et al. The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort. Chest, 2014,146(3):633\u2013643","journal-title":"Chest"},{"issue":"5","key":"2672_CR6","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/JTO.0b013e318287c3eb","volume":"8","author":"N Yanagawa","year":"2013","unstructured":"Yanagawa N, Shiono S, Abiko M, et al. New IASLC\/ATS\/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma. J Thorac Oncol, 2013,8(5):612\u2013618","journal-title":"J Thorac Oncol"},{"key":"2672_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.lungcan.2020.01.007","volume":"141","author":"C Li","year":"2020","unstructured":"Li C, Shen Y, Hu F, et al. Micropapillary pattern is associated with the development of brain metastases and the reduction of survival time in EGFR-mutation lung adenocarcinoma patients with surgery. Lung Cancer, 2020,141:72\u201377","journal-title":"Lung Cancer"},{"issue":"9","key":"2672_CR8","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.21037\/jtd.2018.08.64","volume":"10","author":"M Ma","year":"2018","unstructured":"Ma M, She Y, Ren Y, et al. Micropapillary or solid pattern predicts recurrence free survival benefit from adjuvant chemotherapy in patients with stage IB lung adenocarcinoma. J Thorac Dis, 2018,10(9):5384\u20135393","journal-title":"J Thorac Dis"},{"issue":"3","key":"2672_CR9","doi-asserted-by":"publisher","first-page":"360","DOI":"10.5606\/tgkdc.dergisi.2019.17284","volume":"27","author":"D Yald\u0131z","year":"2019","unstructured":"Yald\u0131z D, Acar A, \u00d6rs Kaya \u015e, et al. Papillary predominant histological subtype predicts poor survival in lung adenocarcinoma. Turk Gogus Kalp Damar Cerrahisi Derg, 2019,27(3):360\u2013366","journal-title":"Turk Gogus Kalp Damar Cerrahisi Derg"},{"issue":"1","key":"2672_CR10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/JTO.0b013e3182769aa8","volume":"8","author":"A Yoshizawa","year":"2013","unstructured":"Yoshizawa A, Sumiyoshi S, Sonobe M, et al. Validation of the IASLC\/ATS\/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol, 2013,8(1):52\u201361","journal-title":"J Thorac Oncol"},{"issue":"9","key":"2672_CR11","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s11748-017-0790-0","volume":"65","author":"H Ito","year":"2017","unstructured":"Ito H, Nakayama H, Murakami, et al. Does the histologic predominance of pathological stage IA lung adenocarcinoma influence the extent of resection? Gen Thorac Cardiovasc Surg, 2017,65(9):512\u2013518","journal-title":"Gen Thorac Cardiovasc Surg"},{"issue":"2","key":"2672_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/jclinpath-2016-204302","volume":"71","author":"T Zombori","year":"2018","unstructured":"Zombori T, Fur\u00e1k J, Ny\u00e1ri T, et al. Evaluation of grading systems in stage I lung adenocarcinomas: a retrospective cohort study. J Clin Pathol, 2018,71(2):135\u2013140","journal-title":"J Clin Pathol"},{"issue":"10","key":"2672_CR13","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.jtho.2020.06.001","volume":"15","author":"AL Moreira","year":"2020","unstructured":"Moreira AL, Ocampo PSS, Xia Y, et al. A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol, 2020,15(10):1599\u20131610","journal-title":"J Thorac Oncol"},{"issue":"2","key":"2672_CR14","first-page":"218","volume":"51","author":"M Ito","year":"2017","unstructured":"Ito M, Miyata Y, Yoshiya T, et al. Second predominant subtype predicts outcomes of intermediate-malignant invasive lung adenocarcinoma. Eur J Cardiothorac Surg, 2017,51(2):218\u2013222","journal-title":"Eur J Cardiothorac Surg"},{"issue":"6","key":"2672_CR15","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1002\/jso.25858","volume":"121","author":"H Li","year":"2020","unstructured":"Li H, Wang Z, Yang F, et al. Development and validation of a nomogram for predicting cancer-specific survival of surgical resected stage I\u2013II adenosquamous carcinoma of the lung. J Surg Oncol, 2020,121(6):1027\u20131035","journal-title":"J Surg Oncol"},{"issue":"7","key":"2672_CR16","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1245\/s10434-019-07318-7","volume":"26","author":"Y Zeng","year":"2019","unstructured":"Zeng Y, Mayne N, Yang CJ, et al. A Nomogram for Predicting Cancer-Specific Survival of TNM 8th Edition Stage I Non-small-cell Lung Cancer. Ann Surg Oncol, 2019,26(7):2053\u20132062","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"2672_CR17","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1200\/JCO.2007.12.9791","volume":"26","author":"A Iasonos","year":"2008","unstructured":"Iasonos A, Schrag D, Raj GV, et al. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol, 2008,26(8):1364\u20131370","journal-title":"J Clin Oncol"},{"issue":"14","key":"2672_CR18","doi-asserted-by":"publisher","first-page":"4400","DOI":"10.1158\/1078-0432.CCR-07-4713","volume":"14","author":"SF Shariat","year":"2008","unstructured":"Shariat SF, Karakiewicz PI, Suardi N, et al. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res, 2008,14(14):4400\u20134407","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2672_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","volume":"56","author":"PJ Heagerty","year":"2000","unstructured":"Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics, 2000,56(2):337\u2013344","journal-title":"Biometrics"},{"issue":"2","key":"2672_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/sim.2929","volume":"27","author":"MJ Pencina","year":"2008","unstructured":"Pencina MJ, D\u2019Agostino RB, Sr., D\u2019Agostino RB, Jr., et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med, 2008,27(2):157\u2013172","journal-title":"Stat Med"},{"issue":"6","key":"2672_CR21","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989X06295361","volume":"26","author":"AJ Vickers","year":"2006","unstructured":"Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making, 2006,26(6):565\u2013574","journal-title":"Med Decis Making"},{"issue":"8","key":"2672_CR22","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/modpathol.2013.227","volume":"27","author":"AC Mackinnon Jr.","year":"2014","unstructured":"Mackinnon AC, Jr., Luevano A, de Araujo LC, et al. Cribriform adenocarcinoma of the lung: clinicopathologic, immunohistochemical, and molecular analysis of 15 cases of a distinctive morphologic subtype of lung adenocarcinoma. Mod Pathol, 2014,27(8):1063\u20131072","journal-title":"Mod Pathol"},{"key":"2672_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.lungcan.2019.09.026","volume":"137","author":"M Kim","year":"2019","unstructured":"Kim M, Chung YS, Kim KA, et al. Prognostic factors of acinar- or papillary-predominant adenocarcinoma of the lung. Lung Cancer, 2019,137:129\u2013135","journal-title":"Lung Cancer"},{"issue":"10","key":"2672_CR24","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1002\/cam4.3012","volume":"9","author":"D Lu","year":"2020","unstructured":"Lu D, Yang J, Liu X, et al. Clinicopathological features, survival outcomes, and appropriate surgical approaches for stage I acinar and papillary predominant lung adenocarcinoma. Cancer Med, 2020,9(10):3455\u20133462","journal-title":"Cancer Med"},{"issue":"3","key":"2672_CR25","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jtcvs.2019.03.090","volume":"158","author":"K Suzuki","year":"2019","unstructured":"Suzuki K, Saji H, Aokage K, et al. Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial. J Thorac Cardiovasc Surg, 2019,158(3):895\u2013907","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"6","key":"2672_CR26","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s00432-020-03180-3","volume":"146","author":"Z Wen","year":"2020","unstructured":"Wen Z, Zhao Y, Fu F, et al. Comparison of outcomes following segmentectomy or lobectomy for patients with clinical N0 invasive lung adenocarcinoma of 2 cm or less in diameter. J Cancer Res Clin Oncol, 2020,146(6):1603\u20131613","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"2672_CR27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/1759-7714.12942","volume":"10","author":"S Cao","year":"2019","unstructured":"Cao S, Teng J, Xu J, et al. Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non-predominant lung adenocarcinoma. Thorac Cancer, 2019,10(2):249\u2013255","journal-title":"Thorac Cancer"},{"issue":"6","key":"2672_CR28","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1245\/s10434-019-08113-0","volume":"27","author":"C Wang","year":"2020","unstructured":"Wang C, Yang J, Lu M. Micropapillary Predominant Lung Adenocarcinoma in Stage IA Benefits from Adjuvant Chemotherapy. Ann Surg Oncol, 2020,27(6):2051\u20132060","journal-title":"Ann Surg Oncol"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-022-2672-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-022-2672-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-022-2672-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T16:11:11Z","timestamp":1672330271000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-022-2672-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2672"],"URL":"https:\/\/doi.org\/10.1007\/s11596-022-2672-7","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"23 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Statement"}}]}}